TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06257693: Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Sponsor: Alessa Therapeutics Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 45 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,382,304

Rescue Site Savings

+$911,064

Unlock Full NCT06257693 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06257693 Rescue Dossier →